POS1139 COMPARISON OF THE FREQUENCY OF DETECTION OF EARLY SIGNS OF ATHEROSCLEROSIS IN PATIENTS WITH CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE AND OSTEOARTHRITIS

Background: Crystal-induced inflammation can significantly increase cardiovascular risk (CVR) and cause early development of atherosclerosis [1]. However, no studies have been performed in patients with calcium pyrophosphate crystal deposition disease (CPPD). Objectives: To compare the presence of atherosclerosis early signs (increased thickness of the intima-media complex (CIMT)) in patients with CPPD and osteoarthritis (OA). Methods: A cross-sectional study included 48 patients, aged 18 to 65 years, 26 patients with crystal-verified diagnosis of CPPD (McCarty criteria) (6 (23%) men and 20 (77%) women) and 22 patients with OA (7 (32%) men and 15 (68%) women). Exclusion criteria are the presence of other rheumatic diseases with symptoms of arthritis, diabetes mellitus, coronary heart disease (CHD), prior myocardial infarction, stroke or myocardial revascularization surgery, estimated glomerular filtration rate (eGFR) 0.9 mm and 1.3 mm was regarded as an atherosclerotic plaque. Statistica 12.0 package was used for statistical data processing. Results: The groups were completely comparable by gender, age and all laboratory parameters (see Table 1), an increase in CRP>5 mg/l was more often detected in patients with CPPD - 31% vs 14% patients with OA (p=0.16). Conclusion: Early signs of atherosclerosis are detected in 50% of patients with CPPD without clinical signs of atherosclerosis and with low or moderate CVR according to SCORE, significantly more often than in patients with OA (23%), which can be reflection of chronic crystal-induced inflammation. References: [1]Hoseini Z, Sepahvand F, Rashidi B, Sahebkar A, Masoudifar A, Mirzaei H. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. J Cell Physiol. 2018 Mar;233(3):2116-2132. doi: 10.1002/jcp.25930. Epub 2017 May 23. PMID: 28345767. Disclosure of Interests: Maxim Elisеev Speakers bureau: Berlin Chemie Menarini Group, Novartis International AG, EGIS, Aleksandra Novikova: None declared, Olga Sheliabina: None declared, Maria Chikina: None declared, Eugenia Markelova: None declared.